Biofrontera Inc. reported a mixed Q1 2026 with a 17% revenue increase to $10.08 million, showing strong sales growth despite missing analyst revenue expectations slightly. The company posted a loss of $0.41 per share, wider than the estimated $0.12 loss but improved from last year's $0.47 loss. Operationally, Biofrontera improved its gross margin to 80% and narrowed its operating loss, signaling progress despite ongoing challenges. These results highlight growth potential amid profitability struggles, with a focus on operational efficiency going forward.
Sun Life Global Investments declared cash distributions for May 2026 for three of its exchange-traded fund (ETF) series. Unitholders of record as of May 22, 2026, will receive payments on May 29, 2026, with amounts ranging from $0.075 to $0.108 per u...
Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in securities fraud class actions against Atara Biotherapeutics, Coty Inc., Super Micro Computer, and ImmunityBio. The lawsuits allege these comp...
Monopar Therapeutics announced a net loss of $3.9 million in Q1 2026, up from $2.6 million in Q1 2025, driven by increased R&D and administrative expenses. The company remains on track to submit its New Drug Application (NDA) for ALXN1840, a treatmen...
Pinnacle Bankshares Corporation announced a 7% increase in its quarterly cash dividend to $0.30 per share, payable June 5, 2026, continuing a streak of 55 consecutive quarters of dividend payments. The company highlighted strong earnings, liquidity, ...
Dime Community Bancshares announced it will continue supporting the Committee for Hispanic Children and Families (CHCF), which provides educational and advocacy programs for underserved children and families in New York City. This ongoing partnership...
